Adavosertib is under clinical development by AstraZeneca and currently in Phase II for Small-Cell Lung Cancer.

Adavosertib is under clinical development by AstraZeneca and currently in Phase II for Triple-Negative Breast Cancer (TNBC).

An Institute for Value-Based Medicine regional event in Houston, Texas, covered inconsistencies with the integration of precision medicine in oncology practices, the evolution of treatment for ...

There are also some signals in the space of lung cancer management ... and this appeared to be enriched for patients who had TP53-wildtype status. The company is planning on expanding into ...

INR:4856. lucky royal casino Three more anti-cancer drugs are planned to be included in the breakthrough therapy! Lung cancer, medullary thyroid cancer… Foun ...

One such example is the FGFR3 gene in lung cancer. This gene of 809 codons has only 8 hits ... (A) Out of 119 CDN-carrying genes (red bars), 87 have only one CDN. For the rest, TP53 possesses the most ...

New research from the University of St Andrews School of Medicine has found that biomarker testing in individuals at risk of ...

Scientists have developed inhalable lung cancer therapeutics utilizing mucoadhesive proteinic nanoparticles.